Photo by theyshane from unsplash
Rosette‐forming glioneuronal tumour (RGNT) is a rare central nervous system (CNS) World Health Organization (WHO) grade 1 brain neoplasm. According to the WHO 2021, essential diagnostic criteria are a ‘biphasic… Click to show full abstract
Rosette‐forming glioneuronal tumour (RGNT) is a rare central nervous system (CNS) World Health Organization (WHO) grade 1 brain neoplasm. According to the WHO 2021, essential diagnostic criteria are a ‘biphasic histomorphology with neurocytic and a glial component, and uniform neurocytes forming rosettes and/or perivascular pseudorosettes associated with synaptophysin expression’ and/or DNA methylation profile of RGNT whereas ‘FGFR1 mutation with co‐occurring PIK3CA and/or NF1 mutation’ are desirable criteria.
Journal Title: Neuropathology and Applied Neurobiology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!